comparemela.com

Latest Breaking News On - Osimertinib - Page 2 : comparemela.com

UNICORN Study: Osimertinib and Other Emerging Treatments for Uncommon EGFR Mutations

Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.

Precision medicineBiomarker testingNon small cell lung cancerLung cancerUnicorn studyUnicorn trialUncommon egfr mutationsExon 20 insertionsIntracranial diseaseExon 18 mutationsExon 21 mutations

FLAURA2: Osimertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.

Evolving treatment paradigmAdvanced nonSmall cell lung cancerNon small cell lung cancerAdvanced non small cell lung cancerAdvanced nsclcNsclc treatmentEgfr mutant lung cancerEgfr mutated lung cancerFirst line treatmentBrain metastases

First-Line Treatment for EGFR-Mutant Advanced Lung Cancer

A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.

Evolving treatment paradigmAdvanced nonSmall cell lung cancerLine treatmentMutant advanced lungNon small cell lung cancerAdvanced non small cell lung cancerAdvanced nsclcNsclc treatmentEgfr mutant lung cancerEgfr mutated lung cancerFirst line treatmentBrain metastases

Treatment Strategies for Uncommon EGFR Mutations in NSCLC

Panelists discuss the intricacies of treating uncommon EGFR mutations, dissecting approved treatment options, considerations for specific mutations, and insights into the evolving drug landscape.

Precision medicineBiomarker testingNon small cell lung cancerUncommon egfr mutationsEgfr mutationsEgfr mutation classificationExon 20 insertion mutationsHeymach classification

Dr Shu on Advances in Adjuvant Therapy For Early-Stage NSCLC

Catherine Ann Shu, MD, discusses key therapeutic advances in the adjuvant setting for patients with early-stage non–small cell lung cancer.

Catherine shuColumbia university herbert irving comprehensive cancer centerThoracic medical oncology servicePrice family associate professorAdjuvant therapy

vimarsana © 2020. All Rights Reserved.